Quest Diagnostics (DGX) is attracting significant attention following a number of key developments. Firstly, a new study has validated DGX's Alzheimer's blood test leading many to speculate that this could challenge the bearish narratives around the company. News around the company's strong Q3 2025 financial results - and the raising of guidance for the full year 2025, has further sparked investor interest. Amidst this, DGX's stock holdings have been increasing, notably by Envestnet Asset Management Inc. and Ashton Thomas Private Wealth LLC. The company's collaboration with Google Cloud to streamline data and personalize customer experiences using generative AI, marks a bold stride towards innovation. Their venture into advanced pharmacogenomics is significant as well, adding to their line of premier lab tests. Strong earnings against expectations combined with their raised outlook could earmark them as a game changer in the bio-tech market. The company's potential is further exemplified in the joint venture with Corewell Health, providing enhanced Laboratory Services in Michigan. Lastly, Quest's significant progress towards Alzheimer's detection with the development of their new blood tests along with the breakthrough designation for their circulating tumor DNA test from the FDA, all add up to the bullish case for the company.
Quest Diagnostics DGX News Analytics from Mon, 27 Jan 2025 08:00:00 GMT to Sat, 01 Nov 2025 11:29:46 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 3
